Related Experiment Video

Updated: Aug 18, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

MEF2A sequence variants and coronary artery disease: a change of heart?

David Altshuler1, Joel N Hirschhorn

  • 1Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA. altshuler@molbio.mhg.harvard.edu

The Journal of Clinical Investigation
|April 21, 2005
PubMed

Insights

Rare MEF2A mutations are not supported as a cause of coronary artery disease (CAD) and myocardial infarction (MI). Sequencing revealed limited evidence linking MEF2A variants to these common cardiovascular conditions.

Area of Science:

  • Genetics
  • Cardiovascular Medicine
  • Molecular Biology

Background:

  • Previous research suggested rare mutations in the MEF2A gene could be linked to coronary artery disease (CAD) and myocardial infarction (MI).
  • This study aimed to investigate the role of MEF2A variants in premature CAD and MI through comprehensive genetic sequencing.

Discussion:

  • The study sequenced MEF2A in 300 premature CAD patients and controls.
  • A single CAD patient harbored a missense mutation absent in controls.
  • A previously implicated 21-bp deletion in MEF2A was found in unaffected individuals, failing to segregate with disease in families.

Key Insights:

  • Genetic sequencing data does not support MEF2A mutations as a common cause of CAD or MI.
  • The findings highlight challenges in establishing causality between genetic variations and complex cardiovascular diseases.
  • The specific 21-bp deletion in MEF2A is unlikely to be a causal factor for CAD/MI.

Outlook:

  • Further research may explore other genetic factors contributing to premature CAD and MI.
  • This study underscores the importance of rigorous genetic association studies for common diseases.
  • Investigating the functional impact of identified MEF2A variants in relevant cellular models could provide further insights.

Related Concept Videos

Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...